Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harpoon Therapeutics Inc (NQ: HARP )

4.000 +0.040 (+1.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Harpoon Therapeutics Inc

Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in September
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023
Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and... 
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics to Participate in the Canaccord Horizons in Oncology Conference
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics Announces Closing of $25 Million Private Placement
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference
From Harpoon Therapeutics
Via GlobeNewswire
MarketBeat: Week in Review 12/12 - 12/16
A triple-witching day means it could be a rough end to a trading week. Before you step away for the holidays, here are some of the top articles from this week. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Harpoon Therapeutics Remains Volatile After Promising News
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%. 
Via MarketBeat
Three Small-Cap Biotech Stocks to Consider Now
This article looks at three small-cap biotech companies with stock prices that are making significant moves and have a bright outlook for 2023 
Via MarketBeat
Harpoon Therapeutics (NASDAQ: HARP) Releases Updated Phase 1 Interim Results for HPN217 in Treating Relapsed Multiple Myeloma
Harpoon Therapeutics, Inc. (NASDAQ: HARP) is engaged as a clinical-stage immune-oncology company, which is focused on the research and development 
Via Spotlight Growth
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition
Updated interim results from Phase 1 clinical trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma to be presented in a poster at ASH on Sunday, December 11, 2022,... 
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer
Harpoon adds experienced drug developer to leadership team 
From Harpoon Therapeutics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.